drugset
drugset / Trial / NCT05239689

Clinical Study of CD38 CAR-T Cells in the Treatment of Hematological Malignancies

NCT05239689 ↗

Phase 0 Unknown 36 enrolled Zhejiang University Yake Biotechnology Ltd. · collab
NaSingle-groupOpen-labelTreatment

Summary

Clinical Study on the Safety and Effectiveness of CD38 CAR-T Cells in the Treatment of CD38-positive Hematological Malignancies

Timeline

Start
2022-02-28
Primary completion
2024-12-05
Completion
2024-12-05

Drugs

EvaluationDrugModalityDoseRoute
Subject CD38 CAR T-cells Cell therapy 2e+06 cells/kg Intravenous
Subject CD38 CAR T-cells Cell therapy 8e+06 cells/kg Intravenous

Indications

acute myeloid leukemia